Clinical Trial Update: Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

View source ↗

Summary

A clinical trial comparing apixaban to warfarin for secondary prevention in non-valvular atrial fibrillation has completed; results were posted in early 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)
• Warfarin (warfarin)

Snippet

Sponsor: Pfizer | Conditions: Non-valvular Atrial Fibrillation | Status: COMPLETED | Results posted: 2024-01-11